PHARMACOLOGICAL APPLICATIONS AND PHARMACOKINETIC MODIFICATIONS OF N-ACETYLCYSTEINE
DOI:
https://doi.org/10.47957/ijpda.v11i1.535Keywords:
N-Acetyl Cysteine, NAC-applications, Pharmacokinetic Modifications-NACAbstract
NAC, an acetylated cysteine compound, is a proteinogenic acid. Being a glutathione recurs or NAC is rather unique because of the multifaceted chemical properties of the cysteinyl thiol group of the molecule. This critical review focuses on the pharmacological applications and pharmacokinetic modifications of NAC to provide a better understanding. NAC was earlier used as a mucolytic agent in various respiratory illnesses and is now widely used as the specific antidote for acetaminophen overdose. In course of time, it has proven to be beneficial in many conditions such as HIV infection, COPD exacerbations, heart diseases, treatment of pulmonary fibrosis, Alzheimer’s, and Parkinson’s disease; helps in the prevention of contrast-induced kidney damage during procedures, etc. Preliminary studies also suggest NAC maintains a major role as cancer chemo protective, adjunct in the eradication of Helicobacter pylori, prophylaxis of gentamicin-induced hearing loss in patients, and also found to have some clinical usefulness as a chelating agent in the treatment of acute heavy metal poisoning. Despite its beneficial traits with limited side effects, bioavailability remains a major concern. Hence different pharmacokinetic modifications of NAC like N-acetyl cysteine amide (NACA), N-acetyl-L-cysteine ethyl ester (NACET), Liposomal-N-acetyl cysteine, Effervescent tablet of N-acetyl cysteine, Acetyl cysteine oral inhalation, etc may ameliorate this major drawback. As a result, to develop a more well-designed and reliable indication; to optimize the dose of NAC, larger controlled trials with longer follow-up sections is demanded in the future. Thus, this review brings forward comprehensive knowledge about the possibilities to introduce NAC as a protective and tolerable medication for these various conditions.
Downloads
References
Yildiz D, Arik M, Cakir Y, Civi Z. Comparison of N-acetyl-L-cysteine and L-cysteinein respect to their transmembrane fluxes. Biochemistry (Moscow) Supplement SeriesA:Membraneand Cell Biology. 2009 Jun;3(2):157-62.
Sun SY. N-acetylcysteine, reactive oxygen species, and beyond. Cancer biology &therapy.2010 Jan 15;9(2):109-10.
Amini A, Masoumi-Moghaddam S, Morris DL. Utility of Bromelain and N-acetylcysteine in treatment of peritoneal dissemination of gastrointestinal mucin-producingmalignancies. Springer;2016 Mar 5.
Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidantbenefits.Pharmacology&therapeutics. 2014 Feb 1;141(2):150-9.
Tenório MC, Graciliano NG, Moura FA, Oliveira AC, Goulart MO. N-Acetylcysteine(NAC): Impacts onHuman Health. Antioxidants.2021 Jun;10(6):967.
Ooi S.L., Green R., Pak S.C. N-Acetylcysteine for the treatment of psychiatricdisorders: Areview of current evidence. BioMedRes. Int.2018;2018:8.doi:10.1155/2018/2469486.
Dodd, S. et al. (2008) N-Acetylcysteine for antioxidant therapy: pharmacology and clinicalutility. Expert Opin. Biol. Ther. 8, 1955– 1962.
Hoffer, E., Baum, Y., Tabak, A., and Taitelman, U., N-Acetylcysteine Increases theGlutathione Content and Protects Rat Alveolar Type II Cells AgainstParaquatInducedCytotoxicity, Toxicol. Lett., 1996, vol. 84, pp.7–12.
Murray, R.K., Granner, D.K., Mayes, P.A., and Rodwell, V.W., Biosynthesis ofNutritionally Nonessential Amino Acids. Harper’s Biochemistry, 22nd Ed., USA:Appletonand Lange, 1991, pp. 267–269.
Griffith, O.W., Biological and Pharmacological Regulation of MammalianGlutathioneSynthesis, FreeRad. Biol. Med., 1999, vol. 27, pp. 922–935.
Sies, H., Glutathione and Its Role in Cellular Functions, Free Rad. Biol. Med., 1999,vol. 27,pp. 916–921.
Bonanomi, L. and Gazzaniga, A., Toxicological, Pharmacokinetic and MetabolicStudieson Acetylcysteine, Eur. J. Respir. Dis.,1980, vols. 45–51, p. 61.
De Caro, L., Ghizzi, A., and Costa, R., Pharmacokinetics and Bioavailability of OralAcetylcysteinein Healthy Volunteers, Arzneim. Forsch.,1989, vol. 39,pp. 382– 385
Bonanomi L, Gazzaniga A. Toxicological, pharmacokinetic and metabolic studies onacetylcysteine. European journal of respiratory diseases. Supplement. 1980;111:45-51.
Sjödin K, Nilsson E, Hallberg A, Tunek A. Metabolism of N-acetyl-l-cysteine Somestructural requirements for the deacetylation and consequences for the oralbioavailability.Biochemical pharmacology.1989Nov15;38(22):3981-5.
Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relationto chronic obstructive pulmonary disease. European Respiratory Journal. 2004 Apr1;23(4):629-36.
Gabard B, Mascher H. Endogenous plasma N-acetylcysteine and single dose oralbioavailability from two different formulations as determined by a new analyticalmethod.Biopharmaceutics&drugdisposition. 1991 Jul;12(5):343-53.
Ates B, Abraham L, Ercal N. Antioxidant and free radical scavenging properties of N-acetylcysteine amide (NACA) and comparison with N-acetylcysteine (NAC). Freeradicalresearch.2008 Jan 1;42(4):372-7.
Bhatti, J., Nascimento, B., Akhtar, U., Rhind, S.G., Tien, H., Nathens, A. and da Luz,L.T.,2018.Systematicreviewofhumanand animalstudiesexaminingtheefficacyandsafety of N-acetylcysteine (NAC) and N-acetylcysteine amide (NACA) in traumatic brain injury: impact on neurof unctional outcome and biomarkers of oxidative stress and inflammation. Frontiers in neurology, 8, p.744.
Grinberg L, Fibach E, Amer J, Atlas D. N-acetylcysteine amide, a novel cell-permeating thiol, restores cellular glutathione and protects human red blood cells from oxidative stress. Free Radical Biology and Medicine. 2005 Jan 1;38(1):136-45.
Giustarini D, Milzani A, Dalle-Donne I, Tsikas D, Rossi R. N-Acetylcysteine ethylester (NACET): a novel lipophilic cell-permeable cysteine derivative with an unusual pharmacokinetic feature and remarkable antioxidant potential. Biochemical pharmacology. 2012 Dec1;84(11):1522-33
Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. Clinical pharmacokinetics. 1991 Feb;20(2):123-34.
Mitsopoulos P, Suntres ZE. Protective effects of liposomal N-acetylcysteine againstparaquat-induced cytotoxicity and gene expression. Journal of toxicology. 2011 Apr4;2011.
Alipour M, Buonocore C, Omri A, Szabo M, Pucaj K, Suntres ZE. Therapeutic effectof liposomal-N-acetylcysteine against acetaminophen-induced hepatotoxicity. Journalofdrug targeting. 2013May1;21(5):466-73.
https://zenodo.org/record/2384877/files/19.pdf?download=1
Bardal SK, Waechter JE, Martin DS. Applied pharmacology. Elsevier HealthSciences;2011
Greene SC, Noonan PK, Sanabria C, Peacock WF. Effervescent N-acetylcysteinetablets versus oral solution N-acetylcysteine in fasting healthy adults: an open-label,randomized, single-dose, crossover, relative bioavailability study. CurrentTherapeuticResearch.2016 Jan 1;83:1-7
Li X, Wei X, Chen C, Zhang Z, Liu D, Hei Z, Yao W. N-Acetylcysteine inhalationimproves pulmonary functionin patients receive dliver transplantation. Bioscience reports.2018 Oct 31;38(5).
TsikasD,SchwedhelmKS,SurdackiA,GiustariniD,RossiR,Kukoc-ModunL,Kedia G, Ückert S. S-Nitroso-N-acetyl-L-cysteine ethyl ester (SNACET) and N-acetyl-L-cysteine ethyl ester (NACET)–Cysteine-based drug candidates with uniquepharmacological profiles for oral use as NO, H2S and GSH suppliers and asantioxidants: Results and overview. Journal of pharmaceutical analysis. 2018 Feb1;8(1):1-9.
Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer’s disease. Neurology. 2001 Oct 23;57(8):1515-7.
Moreira PI, Harris PL, Zhu X, Santos MS, Oliveira CR, Smith MA, Perry G. Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. Journal of Alzheimer's Disease. 2007 Jan 1;12(2):195-206.
Cocco T, Sgobbo P, Clemente M, Lopriore B, Grattagliano I, Di Paola M, Villani G. Tissue-specific changes of mitochondrial functions in aged rats: effect of a long-term dietary treatment with N-acetylcysteine. Free Radical Biology and Medicine. 2005 Mar 15;38(6):796-805.
Slattery J, Kumar N, Delhey L, Berk M, Dean O, Spielholz C, Frye R. Clinical trialsof N-acetylcysteine in psychiatry and neurology: a systematic review. Neuroscience &BiobehavioralReviews.2015 Aug 1;55:294-321.
Minarini A, Ferrari S, Galletti M, Giambalvo N, Perrone D, Rioli G, Galeazzi GM.N-acetylcysteine in the treatment of psychiatric disorders: current status and futureprospects. Expert opinion on drug metabolism & toxicology. 2017 Mar 4;13(3):279-92.
Asevedo E, Mendes AC, Berk M, Brietzke E. Systematic review of N-acetylcysteine in the treatment of addictions. Brazilian Journal of Psychiatry. 2014 Mar 17;36:168-75.
Brown RM, Kupchik YM, Kalivas PW. The story of glutamate in drug addiction and of N-acetylcysteine as a potential pharmacotherapy. Jama Psychiatry. 2013 Sep 1;70(9):895-7.
Garcia RJ, Francis L, Dawood M, Lai ZW, Faraone SV, Perl A. Brief report: attention deficit and hyperactivity disorder scores are elevated and respond to N?acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis & Rheumatism. 2013 May;65(5):1313-8.
Ghanizadeh A, Derakhshan N. N-acetylcysteine for treatment of autism, a case report. Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences. 2012 Oct;17(10):985.
Magalhães PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M. N-acetylcysteine for major depressive episodes in bipolar disorder. Brazilian Journal of Psychiatry. 2011 Dec;33(4):374-8.
Oliver G, Dean O, Camfield D, Blair-West S, Ng C, Berk M, Sarris J. N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review. Clinical Psychopharmacology and Neuroscience. 2015 Apr;13(1):12.
Rodrigues-Barata AR, Tosti A, Rodríguez-Pichardo A, Camacho-Martínez F. N-acetylcysteine in the treatment of trichotillomania. International journal of trichology. 2012 Jul;4(3):176.
Grant JE, Chamberlain SR, Redden SA, Leppink EW, Odlaug BL, Kim SW. N-acetylcysteine in the treatment of excoriation disorder: a randomized clinical trial. JAMA psychiatry. 2016 May 1;73(5):490-6.
Berk M, Jeavons S, Dean OM, Dodd S, Moss K, Gama CS, Malhi GS. Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting. CNS spectrums. 2009 Jul;14(7):357-60.
Yolland CO, Phillipou A, Castle DJ, Neill E, Hughes ME, Galletly C, Smith ZM, Francis PS, Dean OM, Sarris J, Siskind D. Improvement of cognitive function in schizophrenia with N-acetylcysteine: A theoretical review. Nutritional neuroscience. 2020 Feb 1;23(2):139-48.
Prescott LF, Illingworth RN, Critchley JA, Stewart MJ, Adam RD, Proudfoot AT. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J. 1979 Nov 3;2(6198):1097-100.
Schmidt LE, Dalhoff K. Risk factors in the development of adverse reactions to N?acetylcysteine in patients with paracetamol poisoning. British journal of clinical pharmacology. 2001 Jan;51(1):87-91.
ROEDERER M, ELA SW, STAAL FJ, HERZENBERG LA, HERZENBERG LA. N-acetylcysteine: a new approach to anti-HIV therapy. AIDS research and human retroviruses.1992 Feb;8(2):209-17.
Meyer A, Buhl R, Magnussen H. The effect of oral N-acetylcysteine on lungglutathione levels in idiopathic pulmonary fibrosis. European Respiratory Journal.1994Mar1;7(3):431-6.
Dasgupta B, King M. Molecular basis for mucolytic therapy. Canadian RespiratoryJournal.1995;2(4):223-30.
Sadowska AM, Manuel-Y-Keenoy B, De Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and invivo dose-effects: a review. Pulmonary pharmacology & therapeutics. 2007 Feb1;20(1):9-22.
Sanguinetti CM. N-acetylcysteine in COPD: why, how, and when?. Multidisciplinaryrespiratorymedicine. 2015 Dec;11(1):1-1.
Duijvestijn YC, Brand PL. Systematic review of N?acetylcysteine in cystic fibrosis.ActaPaediatrica. 1999 Jan;88(1):38-41
App EM, Baran D, Dab I et al.: Dose-finding and 24-h monitoring for efficacy andsafety of aerosolized nacystelyn in cystic fibrosis. Eur. Respir. J. 19(2), 294–302(2002).
Suk JS, Lai SK, Boylan NJ, Dawson MR, Boyle MP, Hanes J. Rapid transport ofmuco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine.Nanomedicine.2011 Feb;6(2):365-75.
DentonR,KwartH,LittM (1967)N-acetyl cysteine incystic fibrosis.AmRevRespirDis95 : 643-651
Rodenstein D, De Coster A, Gazzaniga A (1978) Pharmacokinetics of oralacetylcysteine: Absorption, binding and metabolism in patients with respiratorydisorders.Clin Pharmacokinet3:247-254
Ratjen F, Wönne R, Posselt HG, Stöver B, Hofmann D, Bender SW. A double-blindplacebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytictreatmentincysticfibrosis.Europeanjournalofpediatrics.1985Nov;144(4):374-8.
Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA.High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation incystic fibrosis. Proceedings of the National Academy of Sciences. 2006 Mar21;103(12):4628-33
Dauletbaev N, Fischer P, Aulbach B, Gross J, Kusche W, Thyroff-Friesinger U,Wagner TO, Bargon J. A phase II study on safety and efficacy of high-dose N-acetylcysteineinpatientswithcysticfibrosis.Europeanjournalofmedicalresearch.2009Dec;14(8):352-8.
Sabri A, Dabbous H, Dowli A, Barazi R. The airway in inhalational injury: diagnosisandmanagement. Annalsof burnsand firedisasters. 2017Mar 31;30(1):24.
Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ. Prevention of radiocontrastnephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. American journal of kidney diseases. 2004Jan1;43(1):1-9.
Palma PC, CJ VJ, NR NJ. N-acetylcysteine in the prevention of cyclophosphamideinducedhaemorrhagic cystitis. Internationalsurgery. 1986Jan 1;71(1):36-7.
Kekec, Z., Seydaoglu, G., Sever, H., Ozturk, F., 2010. The effect of antioxidants(Nacetylcysteine and melatonin) on hypoxia due to carbonmonoxide poisoning.Bratisl.Lek. Listy111 (4), 189–193
Mansour HH, Hasan HF. Protective effect of N-acetylcysteine on cyclophosphamide-induced cardiotoxicity in rats. Environmental Toxicology and Pharmacology. 2015Sep1;40(2):417-22.
Kerr F, Dawson A, Whyte IM, et al. The Australasian Clinical ToxicologyInvestigators Collaboration randomized trial of different loading infusion rates of N-acetylcysteine. Ann Emerg Med. 2005;45(4):402-408.doi:10.1016/j.annemergmed.2004.08.040
Sakamoto S, Muramatsu Y, Satoh K, et al. Effectiveness of combined therapy with pirfeni done and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis:acase-control study. Respirology.2015;20(3):445-452. doi:10.1111/resp.12477
Won HR, Lee GH, Kim JH, et al. Effects of N-acetylcysteine inhalation therapy onthe quality of life of patients with head and neck cancer who are receiving radiationtherapy: a prospective non-randomized controlled multi-center study. J Cancer ResClin Oncol. 2021;147(2):539-547. doi:10.1007/s00432-020-03347-y
Bailey B, McGuigan MA. Management of anaphylactoid reactions to intravenous N-acetylcysteine. Ann Emerg Med. 1998;31(6):710-715. doi:10.1016/s0196-0644(98)70229-x
Mant TG, Tempowski JH, Volans GN, Talbot JC. Adverse reactions to acetylcysteineandeffects of overdose.Br Med J(Clin Res Ed). 1984;289(6439):217-219.doi:10.1136/bmj.289.6439.217
Crowell C, Lyew RV, Givens M, Deering SH. Caring for the mother, concentratingon the fetus: intravenous N-acetylcysteine in pregnancy. Am J Emerg Med.2008;26(6):735.e1-735.e7352.doi:10.1016/j.ajem.2007.11.017
Appelboam AV, Dargan PI, Knighton J. Fatal anaphylactoid reaction to N-acetylcysteine: caution in patients with asthma. Emerg Med J. 2002;19(6):594-595.doi:10.1136/emj.19.6.594
Niemi TT, Munsterhjelm E, Pöyhiä R, Hynninen MS, Salmenperä MT. The effect ofN-acetylcysteine on blood coagulation and platelet function in patients undergoingopen repair of abdominal aortic aneurysm. Blood Coagul Fibrinolysis. 2006;17(1):29-34. doi:10.1097/01.mbc.0000195922.26950.89
Winniford MD, Kennedy PL, Wells PJ, Hillis LD. Potentiation of nitroglycerin-induced coronary dilatation by N-acetylcysteine. Circulation. 1986;73(1):138-142.doi:10.1161/01.cir.73.1.138
Tenenbein PK, Sitar DS, Tenenbein M. Interaction between N-acetylcysteine andactivated charcoal: implications for the treatment of acetaminophen poisoning.Pharmacotherapy.2001;21(11):1331-1336.doi:10.1592/phco.21.17.1331.34427
Ginsburg H, Golenser J. Glutathione is involved in the anti malarial action of chloroquine and its modulation affects drug sensitivity of human and murine species of Plasmodium.RedoxRep.2003;8(5):276-279. doi:10.1179/135100003225002907
Barrios V, Calderón A, Navarro-Cid J, Lahera V, Ruilope LM. N-acetylcysteinepotentiates the antihypertensive effect of ACE inhibitors in hypertensive patients.BloodPress. 2002;11(4):235-239. doi:10.1080/08037050213760
Jang DH, Weaver MD, Pizon AF. In vitro study of N-acetylcysteine on coagulationfactors in plasma samples from healthy subjects. J Med Toxicol. 2013;9(1):49-53.doi:10.1007/s13181-012-0242-2
Nunes TSBS, Rosa LM, Vega-Chacón Y, Mima EGO. Fungistatic Action of N-AcetylcysteineonCandidaalbicans BiofilmsandItsInteractionwithAntifungal Agents. Microorganisms. 2020;8(7):980. Published 2020 Jun 30.doi:10.3390/microorganisms8070980
Šalamon Š, Kramar B, Marolt TP, Poljšak B, Milisav I. Medical and dietary uses ofN-acetylcysteine.Antioxidants. 2019 May;8(5):111.
FDA. Acetadote (acetylcysteine) Injection Package Insert. Available online:https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-539_Acetadote.cfm (accessedon 27 March 2019)
Sadowska AM, Verbraecken J, Darquennes K, De Backer WA. Role of N-acetylcysteine in the management of COPD. International journal of chronicobstructivepulmonarydisease. 2006 Dec;1(4):425.
BavarsadShahripour, R.; Harrigan, M.R.; Alexandrov, A.V. N-acetylcysteine (NAC)in neurological disorders:mechanisms of action and therapeutic opportunities. BrainBehav. 2014, 4, 108–122.
Martina, V.; Masha, A.; Gigliardi, V.R.; Brocato, L.; Manzato, E.; Berchio, A.;Massarenti, P.; Settanni, F.;Della Casa, L.; Bergamini, S.; et al. Long Term N-Acetylcysteine and L-Arginine Administration Reduces Endothelial Activation andSystolic Blood Pressure in Hypertensive Patients with Type 2 DiabetesMellitus.DiabetesCare2008, 31, 940–944.
McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM. Potential role of N-acetylcysteine in the management of substance use disorders.CNS drugs. 2014Feb;28(2):95-106.
Cobley, J.N.; McGlory, C.; Morton, J.P.; Close, G.L. N-Acetylcysteine’s attenuationof fatigue after repeated bouts of intermittent exercise: Practical implications fortournamentsituations.Int. J.Sport Nutr. Exerc.Metab. 2011,21, 451–461.
Luo P, Liu Y, Liu D, Li J. Perspectives for the use of N-acetylcysteine as a candidatedrug to treat COVID-19. Mini Reviews in Medicinal Chemistry. 2021 Feb1;21(3):268-72.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.
